CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

ibrutinib

Last Updated: August 15, 2019
Result type: Reports
Product Line: Reimbursement Review

Generic Name: ibrutinib

Brand Name: Imbruvica

Manufacturer: Janssen Canada Inc.

Indications: Chronic graft versus host disease

Submission Type: Non-submission

Project Status: Not filed

Recommendation Type: CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer